Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model.

Stallmach A, Bokemeyer B, Helwig U, Lügering A, Teich N, Fischer I, Rath S, Lang D, Schmidt C; EPIC Study Group.

Int J Colorectal Dis. 2019 Oct;34(10):1653-1660. doi: 10.1007/s00384-019-03369-0. Epub 2019 Aug 24.

PMID:
31446480
2.

Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.

Brandes A, Groth A, Gottschalk F, Wilke T, Ratsch BA, Orzechowski HD, Fuchs A, Deiters B, Bokemeyer B.

Z Gastroenterol. 2019 Jul;57(7):843-851. doi: 10.1055/a-0903-2938. Epub 2019 Jul 9.

PMID:
31288280
3.

First known case of paediatric inflammatory bowel disease in a western lowland gorilla may be linked to a familial mutation in the MEFV gene.

Petersen BS, Bokemeyer B, Wenker C, Hoby S, Baumgartner K, Will H, Hoeppner MP, Schreiber S, Mecklenburg I, Franke A.

Gut. 2019 Jun 21. pii: gutjnl-2019-319051. doi: 10.1136/gutjnl-2019-319051. [Epub ahead of print] No abstract available.

4.

Correction: Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.

Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; T2D-GENES Consortium, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ.

PLoS Genet. 2019 May 30;15(5):e1008190. doi: 10.1371/journal.pgen.1008190. eCollection 2019 May.

5.

Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study.

Bokemeyer B, Luehr D, Helwig U, Maaser C, Jessen P, Schreiber S.

Eur J Gastroenterol Hepatol. 2019 Jul;31(7):766-772. doi: 10.1097/MEG.0000000000001410.

PMID:
31082999
6.

Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis.

Petruo VA, Krauss E, Kleist A, Hardt J, Hake K, Peirano J, Krause T, Ehehalt R, von Arnauld de la Perriére P, Büning J, Treml O, Krauss N, Albrecht H, Felten G, Hermannspahn U, Burkhardt U, Eisold M, Teich N, Siegmund B, Maaser C, Bokemeyer B, Baumgart DC, Neurath MF, Mudter J; German IBD Study Group (GISG) KND.

Z Gastroenterol. 2019 Apr;57(4):473-483. doi: 10.1055/a-0838-6371. Epub 2019 Apr 9.

PMID:
30965377
7.

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S.

Inflamm Bowel Dis. 2019 May 4;25(6):1028-1035. doi: 10.1093/ibd/izy323.

8.

[Ustekinumab - Current position].

Siegmund B, Högenauer C, Novacek G, Petritsch W, Reinisch W, Schoepfer A, Schreiber S, Vavricka S, Bokemeyer B; für die IBD-Dach-Gruppe.

Z Gastroenterol. 2018 Sep;56(9):1077-1086. doi: 10.1055/a-0655-2425. Epub 2018 Aug 13. Review. German.

PMID:
30103222
9.

Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.

Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; T2D-GENES Consortium, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ.

PLoS Genet. 2018 May 24;14(5):e1007329. doi: 10.1371/journal.pgen.1007329. eCollection 2018 May. Erratum in: PLoS Genet. 2019 May 30;15(5):e1008190.

10.

Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis.

Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B.

Z Gastroenterol. 2018 Oct;56(10):1267-1275. doi: 10.1055/a-0605-4080. Epub 2018 May 9.

PMID:
29742780
11.

Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis.

Wittig BM, Sabat R, Holzlöhner P, Witte-Händel E, Heilmann K, Witte K, Triebus J, Tzankov A, Laman JD, Bokemeyer B, Terracciano L, Schwärzler C, Kohler H, Volkmer R, Loddenkemper C, Wolk K, Hoffmann U, Günthert U.

Mucosal Immunol. 2018 May;11(3):846-860. doi: 10.1038/mi.2017.98. Epub 2017 Nov 29.

PMID:
29186109
12.

Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD).

Langbrandtner J, Hüppe A, Jessen P, Büning J, Nikolaus S, Raspe H, Bokemeyer B.

Clin Exp Gastroenterol. 2017 Sep 4;10:215-227. doi: 10.2147/CEG.S135346. eCollection 2017.

13.

Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.

Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H.

Dig Liver Dis. 2017 Oct;49(10):1086-1091. doi: 10.1016/j.dld.2017.07.010. Epub 2017 Aug 1.

14.

Azathioprine allows glucocorticoid withdrawal - post hoc results of a prospective study in patients with inflammatory bowel diseases.

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Siegmund B, Schmidt C, Stallmach A; German IBD Study group.

Z Gastroenterol. 2017 May;55(5):461-465. doi: 10.1055/s-0043-106310. Epub 2017 May 12.

PMID:
28499322
15.

Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence.

Nikolaus S, Schreiber S, Siegmund B, Bokemeyer B, Bästlein E, Bachmann O, Görlich D, Hofmann U, Schwab M, Kruis W.

J Crohns Colitis. 2017 Sep 1;11(9):1052-1062. doi: 10.1093/ecco-jcc/jjx062.

PMID:
28486634
16.

[Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].

Bokemeyer B, Dignaß A, Schreiber S.

Z Gastroenterol. 2017 Apr;55(4):369-374. doi: 10.1055/s-0042-121520. Epub 2017 Jan 5. German.

PMID:
28056484
17.

Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD.

Teich N, Bokemeyer B, Mohl W, Walldorf J, Bruns T, Schmidt C, Stallmach A; German IBD Study Group.

Gut. 2017 Aug;66(8):1531-1532. doi: 10.1136/gutjnl-2016-313138. Epub 2016 Nov 14. No abstract available.

PMID:
27849560
18.

[Biosimilars in inflammatory bowel disease].

Siegmund B, Atreya R, Bokemeyer B, Kruis W, Mudter J, Sander C, Schreiber S, Reindl W, Zeissig S, Kucharzik T.

Z Gastroenterol. 2016 Nov;54(11):1217-1222. Epub 2016 Oct 6. Review. German.

PMID:
27711946
19.

[Put to Test: Medical Inpatient Rehabilitation of Inflammatory Bowel Diseases].

Hüppe A, Steimann G, Janotta M, Langbrandtner J, Eisemann N, Bokemeyer B, Raspe H.

Rehabilitation (Stuttg). 2016 Aug;55(4):248-55. doi: 10.1055/s-0042-109590. Epub 2016 Aug 16. German.

PMID:
27529302
20.

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group.

Aliment Pharmacol Ther. 2016 Aug;44(3):259-70. doi: 10.1111/apt.13665. Epub 2016 May 29.

21.

Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.

Bokemeyer B, Krummenerl A, Maaser C, Howaldt S, Mroß M, Mallard N.

Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):229-238. doi: 10.1007/s13318-016-0334-5.

PMID:
27101422
22.

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.

Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S; Vedolizumab Germany Consortium.

Aliment Pharmacol Ther. 2016 May;43(10):1090-102. doi: 10.1111/apt.13594. Epub 2016 Apr 1.

23.

Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study.

Peyrin-Biroulet L, Van Assche G, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S.

Dig Liver Dis. 2016 Jun;48(6):601-7. doi: 10.1016/j.dld.2016.01.013. Epub 2016 Mar 2.

PMID:
27012447
24.

[Inflammatory Bowel Disease Competence Network].

Schreiber S, Hartmann H, Kruis W, Kucharzik T, Mudter J, Siegmund B, Stallmach A, Witte C, Fitzke K, Bokemeyer B.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):465-74. doi: 10.1007/s00103-016-2317-8. German.

PMID:
26968556
25.

Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study.

Van Assche G, Peyrin-Biroulet L, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S.

Dig Liver Dis. 2016 Jun;48(6):592-600. doi: 10.1016/j.dld.2016.01.011. Epub 2016 Jan 29.

PMID:
26935454
26.

Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity.

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismüller J, Drabik A, Stallmach A; German IBD Study Group.

J Crohns Colitis. 2016 Jan;10(1):61-8. doi: 10.1093/ecco-jcc/jjv188. Epub 2015 Oct 13.

27.

Addressing unmet needs in inflammatory bowel disease.

Bokemeyer B.

Drug Discov Today. 2015 Sep;20(9):1037-9. doi: 10.1016/j.drudis.2015.07.005. Epub 2015 Jul 29. No abstract available.

PMID:
26232319
28.

[Current position on Vedolizumab for ulcerative colitis and Crohn's disease].

Schreiber S, Dignass AU, Hartmann H, Kruis W, Rogler G, Siegmund B, Stallmach A, Witte C, Bokemeyer B.

Z Gastroenterol. 2015 Jun;53(6):591-602. doi: 10.1055/s-0034-1399400. Epub 2015 May 27. Review. German.

29.

[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)].

van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO.

Rev Gastroenterol Mex. 2015 Jan-Mar;80(1):74-106. doi: 10.1016/j.rgmx.2014.10.008. Epub 2015 Mar 11. Spanish. No abstract available.

30.

Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Büning C, Howaldt S, Stallmach A; AEGIS Study Group.

Inflamm Bowel Dis. 2015 Mar;21(3):579-88. doi: 10.1097/MIB.0000000000000314.

31.

[Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014].

Preiß JC, Bokemeyer B, Buhr HJ, Dignaß A, Häuser W, Hartmann F, Herrlinger KR, Kaltz B, Kienle P, Kruis W, Kucharzik T, Langhorst J, Schreiber S, Siegmund B, Stallmach A, Stange EF, Stein J, Hoffmann JC; German Society of Gastroenterology.

Z Gastroenterol. 2014 Dec;52(12):1431-84. doi: 10.1055/s-0034-1385199. Epub 2014 Dec 4. German. No abstract available.

PMID:
25474283
32.

[Azathioprine in Crohn's disease therapy--guidance against the background of recent studies].

Schmidt C, Herrlinger K, Siegmund B, Bokemeyer B, Schreiber S, Stallmach A; Kompetenznetz Darmerkrankungen.

Z Gastroenterol. 2014 Dec;52(12):1423-30. doi: 10.1055/s-0034-1385650. Epub 2014 Dec 4. Review. German.

PMID:
25474282
33.

[Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].

Schreiber S, Luger T, Mittendorf T, Mrowietz U, Müller-Ladner U, Schröder J, Stallmach A, Bokemeyer B.

Dtsch Med Wochenschr. 2014 Nov;139(47):2399-404. doi: 10.1055/s-0034-1387371. Epub 2014 Nov 12. German.

PMID:
25390629
34.

Parameters of a severe disease course in ulcerative colitis.

Stallmach A, Nickel L, Lehmann T, Bokemeyer B, Bürger M, Hüppe D, Kruis W, Nikolaus S, Preiss JC, Sturm A, Teich N, Schmidt C.

World J Gastroenterol. 2014 Sep 21;20(35):12574-80. doi: 10.3748/wjg.v20.i35.12574.

35.

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.

Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, Moog G, Pape S, Weber B, Isernhagen K, Sandow P, Bokemeyer B, Alshuth U, Steffens H, Hüppe D.

PLoS One. 2014 Sep 19;9(9):e107592. doi: 10.1371/journal.pone.0107592. eCollection 2014.

36.

Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II).

Egan L, D'Inca R, Jess T, Pellino G, Carbonnel F, Bokemeyer B, Harbord M, Nunes P, Van der Woude J, Selvaggi F, Triantafillidis J.

J Crohns Colitis. 2014 Jan;8(1):19-30. doi: 10.1016/j.crohns.2013.04.009. Epub 2013 May 7. Review.

37.

Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis.

Kruis W, Katalinic A, Klugmann T, Franke GR, Weismüller J, Leifeld L, Ceplis-Kastner S, Reimers B, Bokemeyer B.

J Crohns Colitis. 2013 Aug;7(7):e263-70. doi: 10.1016/j.crohns.2012.10.012. Epub 2012 Nov 20.

PMID:
23182164
38.

Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.

Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C; FERGI Study Group.

Clin Gastroenterol Hepatol. 2013 Mar;11(3):269-77. doi: 10.1016/j.cgh.2012.10.013. Epub 2012 Oct 16.

PMID:
23078888
39.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.

Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO; European Crohn's and Colitis Organisation.

J Crohns Colitis. 2013 Feb;7(1):1-33. doi: 10.1016/j.crohns.2012.09.005. Epub 2012 Oct 3. No abstract available.

40.

Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.

Bokemeyer B, Hardt J, Hüppe D, Prenzler A, Conrad S, Düffelmeyer M, Hartmann P, Hoffstadt M, Klugmann T, Schmidt C, Weismüller J, Mittendorf T, Raspe H.

J Crohns Colitis. 2013 Jun;7(5):355-68. doi: 10.1016/j.crohns.2012.02.014. Epub 2012 Apr 12.

PMID:
22503168
41.

Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.

Bokemeyer B, Hommes D, Gill I, Broberg P, Dignass A.

J Crohns Colitis. 2012 May;6(4):476-82. doi: 10.1016/j.crohns.2011.10.006. Epub 2011 Nov 10.

PMID:
22398060
42.

Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease.

Wenger S, Nikolaus S, Howaldt S, Bokemeyer B, Sturm A, Preiss JC, Schoepfer AM, Stallmach A, Schmidt C.

J Crohns Colitis. 2012 Feb;6(1):21-8. doi: 10.1016/j.crohns.2011.06.006. Epub 2011 Jul 18.

PMID:
22261524
43.

[Epidemiology and clinical characteristics of patients with chronic hepatitis B (CHB) in Germany - results of a nationwide cross-sectional study].

Fischer C, Mauss S, Zehnter E, Bokemeyer B, Heyne R, Hüppe D.

Z Gastroenterol. 2012 Jan;50(1):22-9. doi: 10.1055/s-0031-1281628. Epub 2012 Jan 5. German.

PMID:
22222794
44.

[Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011].

Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann JC, Stallmach A.

Z Gastroenterol. 2011 Sep;49(9):1276-341. doi: 10.1055/s-0031-1281666. Epub 2011 Aug 24. German. No abstract available.

PMID:
21866493
45.

[Pharmacotherapy in patients with ulcerative colitis].

Scherer M, Hardt J, Blozik E, Preiss JC, Bokemeyer B, Hüppe A, Raspe H.

Z Gastroenterol. 2011 Jul;49(7):820-6. doi: 10.1055/s-0031-1273276. Epub 2011 Jul 15. German.

PMID:
21766260
46.

FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.

Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C; FERGI Study Group.

Gastroenterology. 2011 Sep;141(3):846-853.e1-2. doi: 10.1053/j.gastro.2011.06.005. Epub 2011 Jun 12.

PMID:
21699794
47.

Health care costs and their predictors of inflammatory bowel diseases in Germany.

Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T.

Eur J Health Econ. 2011 Jun;12(3):273-83. doi: 10.1007/s10198-010-0281-z. Epub 2010 Oct 22.

PMID:
20967482
48.

A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.

Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D; Semapimod-CD04/CD05 Investigators.

Gut. 2010 Jun;59(6):760-6. doi: 10.1136/gut.2009.179994.

PMID:
20551461
49.

[Inflammatory bowel diseases as multi-focal disorders: results from a multi-regional survey on bodily and psychosocial problems in IBD patients].

Hardt J, Muche-Borowski C, Conrad S, Balzer K, Bokemeyer B, Raspe H.

Z Gastroenterol. 2010 Mar;48(3):381-91. doi: 10.1055/s-0028-1109524. German.

PMID:
20221992
50.

[Costs of ulcerative colitis within the German Statutory Health Insurance].

Prenzler A, Bokemeyer B, Mittendorf T, von der Schulenburg JM.

Dtsch Med Wochenschr. 2010 Feb;135(7):281-6. doi: 10.1055/s-0029-1244848. Epub 2010 Feb 9. German.

PMID:
20146156

Supplemental Content

Loading ...
Support Center